Last reviewed · How we verify
NCT06761729: JT821
The Ketogenic Diet in the Treatment of Behavioral Variant Frontotemporal Dementia
NA trial testing Ketogenic diet in Behavioral Variant Frontotemporal Dementia in 3 participants. Not yet recruiting.
31 August 2025
Quick facts
| Lead sponsor | Xuanwu Hospital, Beijing |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 10 February 2025 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 October 2025 |
Drugs / interventions tested
- Ketogenic diet — full drug profile →
Conditions studied
- Behavioral Variant Frontotemporal Dementia — all drugs for Behavioral Variant Frontotemporal Dementia →
Sponsor
Xuanwu Hospital, Beijing
Who can join
Adults 45 to 70, any sex, with Behavioral Variant Frontotemporal Dementia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an exploratory clinical research on the use of JT821 (a ketogenic diet formulation) for the treatment of patients with behavioral variant frontotemporal dementia (bvFTD), aiming to evaluate the effectiveness, safety, and tolerability of JT821 in the intervention of bvFTD. The ketogenic diet (KD) is a low-carbohydrate, adequate protein and high-fat diet. KD was shown to be effective in treating different neurodegenerative diseases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06761729
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ketogenic diet
Trials testing the same drug.
- NCT07495267 — Nutritional Ketosis Marfan · NA · not yet recruiting
- NCT07415590 — Ketogenic Diet for Post-Traumatic Stress Disorder (PTSD) · NA · not yet recruiting
- NCT03991897 — Nutritional Ketosis: a Novel Metabolic Strategy to Treat Lymphedema Patients? · NA · recruiting
- NCT07479095 — Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic · NA · recruiting
- NCT06963437 — Interventions for Weight Regain After Bariatric Surgery · NA · completed
Other Xuanwu Hospital, Beijing trials
Trials by the same sponsor.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
- NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
- NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
- NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06761729 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
- Last refreshed: 10 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06761729.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing